Summit and Akeso report ivonescimab's survival benefit in lung cancer, boosting approval odds and positioning it as a Keytruda challenger. Latest Ratings for SMMT Date Firm Action From To Nov 2020 HC Wainwright & Co. Downgrades Buy Neutral Mar 2020 HC Wainwright & Co. Initiates Coverage On Buy Jun 2018 Janney Montgomery Scott Downgrades Buy Neutral View More Analyst Ratings for SMMT View the Latest Analyst Ratings read more